Open AccessA phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer
Author(s) -
B. H. O'Neil,
A. J. Scott,
W. W. Ma,
S. J. Cohen,
D. L. Aisner,
A. R. Menter,
M. A. Tejani,
J. K. Cho,
J. Granfortuna,
L. Coveler,
Olugbenga Olowokure,
J. C. Baranda,
M. Cusnir,
P. Phillip,
J. Boles,
R. Nazemzadeh,
M. Rarick,
D. J. Cohen,
J. Radford,
L. Fehrenbacher,
R. Bajaj,
V. Bathini,
P. Fanta,
J. Berlin,
A. J. McRee,
R. Maguire,
F. Wilhelm,
M. Maniar,
A. Jimeno,
C. L. Gomes,
Wells A. Messersmith
Publication year - 2015
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/gbtr-cn80
Subject(s) - gemcitabine , pancreatic cancer , medicine , oncology , phases of clinical research , randomized controlled trial , deoxycytidine , cancer , clinical trial